Acceleration of delayed growth with XXXX .

@entity1 @entity6240
61 @entity1 with constitutional delay of growth and maturation, aged 9-19 years and with a bone age (BA) lag of 1.3-5.5 years, were administered @entity6240 (0.05-0.24 mg/kg daily orally, relative dose increasing with age) to accelerate growth. The therapy was continuous and lasted 0.4-3.6 years. The findings are compared with 37 observation periods in a similar group of untreated @entity1 . Growth velocity increased in every treated @entity1 during the therapy, the mean first-year increment being 4.3 +/- 1.6 cm/year. For most @entity1 this brought about a decrease in the height difference from peers, and so afforded the psychosocial relief that was the objective of the therapy. After therapy the velocity decreased slightly in most @entity1 , from a mean of 9.1 +/- 1.4 to 7.1 +/- 3.3 cm/year. The effect of the intervention on final height was assessed by three relatively independent methods of prediction. These were found to be equally valid in the 15 control @entity1 for whom final heights are known. The effect appeared to vary individually, but on the average there appeared to be no loss of height potential. No individual @entity1 with initial BA greater than 10.5 years showed a substantial reduction in predicted final height.
